Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes

Abstract

BackgroundNo targeted immunotherapies reverse type 1 diabetes in humans. However, in a rodent model of type 1 diabetes, Bacillus Calmette-Guerin (BCG) reverses disease by restoring insulin secretion. Specifically, it stimulates innate immunity by inducing the host to produce tumor necrosis factor (TNF), which, in turn, kills disease-causing autoimmune cells and restores pancreatic beta-cell function through regeneration.Methodology/Principal FindingsTranslating these findings to humans, we administered BCG, a generic vaccine, in a proof-of-principle, double-blind, placebo-controlled trial of adults with long-term type 1 diabetes (mean: 15.3 years) at one clinical center in North America. Six subjects were randomly assigned to BCG or placebo and compared to self, healthy paired controls (n = 6) or reference subjects with (n = 57) or without (n = 16) type 1 diabetes, depending upon the outcome measure. We monitored weekly blood samples for 20 weeks for insulin-autoreactive T cells, regulatory T cells (Tregs), glutamic acid decarboxylase (GAD) and other autoantibodies, and C-peptide, a marker of insulin secretion. BCG-treated patients and one placebo-treated patient who, after enrollment, unexpectedly developed acute Epstein-Barr virus infection, a known TNF inducer, exclusively showed increases in dead insulin-autoreactive T cells and induction of Tregs. C-peptide levels (pmol/L) significantly rose transiently in two BCG-treated subjects (means: 3.49 pmol/L [95% CI 2.95–3.8], 2.57 [95% CI 1.65–3.49]) and the EBV-infected subject (3.16 [95% CI 2.54–3.69]) vs.1.65 [95% CI 1.55–3.2] in reference diabetic subjects. BCG-treated subjects each had more than 50% of their C-peptide values above the 95th percentile of the reference subjects. The EBV-infected subject had 18% of C-peptide values above this level.Conclusions/SignificanceWe conclude that BCG treatment or EBV infection transiently modified the autoimmunity that underlies type 1 diabetes by stimulating the host innate immune response. This suggests that BCG or other stimulators of host innate immunity may have value in the treatment of long-term diabetes.Trial RegistrationClinicalTrials.gov NCT00607230

Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS

“…Repeated vaccinations may be an option (as recently reported for patients with insulin-dependent diabetes mellitus). 31 However, considering the duration of the favorable effects in MS, more "relaxed" vaccination schedules may be possible, hence reassuring against possible harms of too frequent immunizations (hyperergic reactions, and T helper 17-dependent tissue damage). 32 Taken as a whole, our results warrant future phase 3 trials in people with CIS, with additional outcome measures (whole brain and gray matter atrophy, among others) especially aimed at verifying a potential neuroprotective effect.…”

Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities

“…Another pilot study involved the use of Bacillus Calmette-Guérin (BCG) vaccine in six subjects with long-standing T1D who were randomized to receive either two doses of BCG or placebo (32). The authors claimed that the BCG subjects, and one of the three control subjects who developed acute Epstein-Barr virus (EBV) infection, showed increases in dead insulin-autoreactive T cells and induction of regulatory T cells.…”

Prevention Opportunities of Type 1 Diabetes in Children

“…Results of the study led by Denise Faustman are being published in the open-access journal PLoS ONE, and a larger Phase II trial is currently underway [30].…”